BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 11859164)

  • 1. Cancer research. Obstacle for promising cancer therapy.
    Marx J
    Science; 2002 Feb; 295(5559):1444. PubMed ID: 11859164
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiangiogenic therapy and p53.
    Hammond EM; Giaccia AJ
    Science; 2002 Jul; 297(5581):471; discussion 471. PubMed ID: 12142499
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of p53 status on tumor response to antiangiogenic therapy.
    Yu JL; Rak JW; Coomber BL; Hicklin DJ; Kerbel RS
    Science; 2002 Feb; 295(5559):1526-8. PubMed ID: 11859195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis. A boost for tumor starvation.
    Marx J
    Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiangiogenic therapy and p53.
    Browder T; Folkman J; Hahnfeldt P; Heymach J; Hlatky L; Kieran M; Rogers MS
    Science; 2002 Jul; 297(5581):471; discussion 471. PubMed ID: 12143876
    [No Abstract]   [Full Text] [Related]  

  • 6. Antitumor interaction of short course endostatin and ionizing radiation.
    Greenberger JS
    Cancer J; 2000; 6(5):279-81. PubMed ID: 11079164
    [No Abstract]   [Full Text] [Related]  

  • 7. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

  • 8. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
    Li D; Williams JI; Pietras RJ
    Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.
    Folkman J
    Exp Cell Res; 2006 Mar; 312(5):594-607. PubMed ID: 16376330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic prospects of angiogenesis inhibitors in cancerology].
    Bout JC; Soncin F; Vandenbunder B
    Rev Mal Respir; 1999 Nov; 16(5):854-5. PubMed ID: 10612161
    [No Abstract]   [Full Text] [Related]  

  • 11. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells.
    He GA; Luo JX; Zhang TY; Hu ZS; Wang FY
    Biochem Biophys Res Commun; 2004 May; 318(2):354-60. PubMed ID: 15120609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic chemotherapy: teaching old drugs new tricks?
    Vogelzang N
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):432-3. PubMed ID: 16163217
    [No Abstract]   [Full Text] [Related]  

  • 13. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
    Gagne P; Akalu A; Brooks PC
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optical imaging and tumor angiogenesis.
    Lin PC
    J Cell Biochem; 2003 Oct; 90(3):484-91. PubMed ID: 14523982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of the orthotopic model to validate antivascular therapies for cancer.
    Loi M; Di Paolo D; Becherini P; Zorzoli A; Perri P; Carosio R; Cilli M; Ribatti D; Brignole C; Pagnan G; Ponzoni M; Pastorino F
    Int J Dev Biol; 2011; 55(4-5):547-55. PubMed ID: 21858775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel agents target existing tumor vasculature.
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):303. PubMed ID: 20235388
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical translation of angiogenesis inhibitors.
    Kerbel R; Folkman J
    Nat Rev Cancer; 2002 Oct; 2(10):727-39. PubMed ID: 12360276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
    Rafii S; Lyden D; Benezra R; Hattori K; Heissig B
    Nat Rev Cancer; 2002 Nov; 2(11):826-35. PubMed ID: 12415253
    [No Abstract]   [Full Text] [Related]  

  • 19. Taking down tumors: vascular disrupting agents entering clinical trials.
    O'Hanlon LH
    J Natl Cancer Inst; 2005 Sep; 97(17):1244-5. PubMed ID: 16145041
    [No Abstract]   [Full Text] [Related]  

  • 20. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".
    Rak J; Yu JL
    Semin Cancer Biol; 2004 Apr; 14(2):93-104. PubMed ID: 15018893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.